IgG annual prevalence was significantly lower than during phase 2, at approximately 10–15% (Fig 2A), and a steep drop in the number of new infections was observed, with IgM prevalence in 2010–11 being only 4% (N = 109, n = 4, 95% CI [0–7]) (Fig 2B). Here, CD40LG is linked to infection.